Lenalidomide

In the US, Lenalidomide (lenalidomide systemic) is a member of the following drug classes: miscellaneous antineoplastics, other immunosuppressants and is used to treat Anemia and Multiple Myeloma.

US matches:

• Lenalidomide

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L04AX04

CAS registry number (Chemical Abstracts Service)

0191732-72-6

Chemical Formula

C13-H13-N3-O3

Molecular Weight

259

Therapeutic Categories

Antineoplastic agent

Immunomodulator

Chemical Names

(3RS)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidin-2,6-dion (IUPAC)

(3RS)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione (WHO)

Foreign Names

• Lenalidomidum (Latin)
• Lenalidomid (German)
• Lenalidomide (French)
• Lenalidomida (Spanish)

Generic Names

• Lenalidomide (OS: BAN, USAN)
• CC-5013 (IS: Cellgene-Corporation)
• CC-5053 (IS)
• CDC-5013 (IS)
• ENMD-0997 (IS)
• IMiD3 (IS)

Brand Names

• Revlimid
  Celgene, Austria; Celgene, Australia; Celgene, Belgium; Celgene, Switzerland; Celgene, Germany; Celgene, Spain; Celgene, France; Celgene, United Kingdom; Celgene, Netherlands; Celgene, Norway; Celgene, Sweden; Celgene, United States; Celgene Europe, Denmark; Celgene International, Slovenia

International Drug Name Search

Glossary

BAN	British Approved Name
IUPAC	International Union of Pure and Applied Chemistry
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.